A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.
Camilla GuerreroNoemi PuigMaría-Teresa CedenaIbai GoicoecheaCristina PerezJuan-José GarcésCirino BottaMaría-José CalasanzNorma C GutierrezMaria-Luisa Martin-RamosAlbert OriolRafael Rios-TamayoMiguel-Teodoro HernandezRafael Martinez-MartinezJoan BargayFelipe De ArribaLuis PalomeraAna Pilar Gonzalez-RodriguezAdrian Mosquera-OrgueiraMarta-Sonia Gonzalez-PerezJoaquin Martinez-LopezJuan-José LahuertaLaura RosinolJoan BladeMaria-Victoria MateosJesus F San-MiguelBruno PaivaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
It is possible to accurately predict MRD outcomes using an integrative, weighted model defined by machine learning algorithms. This is a new concept toward individualized treatment in multiple myeloma. See related commentary by Pawlyn and Davies, p. 2482.